Ultragenyx Pharmaceutical Inc. develops and commercializes therapies for serious rare and ultra-rare genetic diseases. Company news commonly covers revenue from approved medicines such as Crysvita, Dojolvi, and Mepsevii, financial guidance, and updates to a portfolio of approved therapies and product candidates for diseases with high unmet medical need and clear biology.
Recurring developments include FDA interactions and clinical data for investigational programs such as UX111 for Sanfilippo syndrome type A, GTX-102 for Angelman syndrome, UX016 for GNE myopathy, and AAV gene therapy candidates for rare metabolic disorders. Updates also include healthcare conference participation, employment inducement equity grants under Nasdaq rules, and corporate restructuring or expense-management actions when disclosed.
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) announced on July 20, 2022, the grant of stock options for 10,240 shares and 5,120 restricted stock units to a newly hired non-executive officer. These awards, part of the Ultragenyx Employment Inducement Plan, were approved by the compensation committee. The stock options have a ten-year term with an exercise price of $64.75 per share. The restricted stock units and options have a vesting schedule of four years, contingent on continued employment. This reflects the company’s commitment to attracting talent within the biopharmaceutical sector.
Ultragenyx Pharmaceutical (NASDAQ: RARE) has announced interim data from its Phase 1/2 study of GTX-102 for Angelman syndrome, showing good tolerability and clinical activity across multiple domains. The UK and Canadian health authorities have approved dose escalation to higher amounts, starting at 7.5 mg and reaching up to 14 mg. Ultragenyx has also completed a $75 million acquisition of GeneTx. Early results indicate significant improvements in clinical symptoms, with no treatment-related serious adverse events noted.
Ultragenyx Pharmaceutical (NASDAQ: RARE) announced the sale of 30% of its royalty interest from Kyowa Kirin on Crysvita sales in the U.S. and Canada to OMERS for $500 million. This deal, effective from April 2023, caps total payments at 1.45 times the purchase price. Crysvita has achieved over $1.3 billion in net sales in its first four years, marking a successful launch. The proceeds from this non-dilutive financing will support ongoing commercialization and clinical development activities.
NOVATO, Calif., June 10, 2022 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical, focused on rare genetic diseases, announced that CEO Emil D. Kakkis and CFO Mardi Dier will present at the Goldman Sachs Global Healthcare Conference on June 16, 2022, at 10:00 AM PDT in Palos Verdes, CA. The live and archived webcast will be available on the company’s website for 90 days. Ultragenyx aims to develop novel therapies for rare diseases with unmet medical needs, showcasing a commitment to effective and timely drug development.
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) announced that CEO Emil D. Kakkis will present at the Jefferies Global Healthcare Conference on June 8, 2022, at 2:30 PM ET, in New York. The presentation will focus on the company's commitment to developing therapies for serious rare genetic diseases. A live and archived webcast will be available on their website for 90 days post-event. Ultragenyx aims to deliver effective treatments efficiently, addressing high unmet medical needs in rare diseases.
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) revealed promising long-term efficacy and safety data for its investigational gene therapies DTX401 and DTX301 during recent presentations. Phase 1/2 studies show DTX401 for Glycogen Storage Disease Type Ia (GSDIa) sustained responses for over 3.5 years, with 70% mean reduction in cornstarch intake. DTX301 for Ornithine Transcarbamylase (OTC) deficiency demonstrated durable metabolic control for over four years, with significant improvements in patient responses. No serious adverse events reported across both studies, highlighting the therapies’ safety profiles.
Ultragenyx Pharmaceutical (NASDAQ: RARE) and Abeona Therapeutics (NASDAQ: ABEO) have entered into an exclusive license agreement for the gene therapy ABO-102 (now UX111) for treating Sanfilippo syndrome type A (MPS IIIA). Ultragenyx will oversee the program, while Abeona is eligible for tiered royalties up to 10% on net sales post-approval. The ongoing Transpher A trial shows promising interim results, indicating preserved neurocognitive development and no serious adverse events. The therapy has received multiple designations from the FDA and EMA, highlighting its potential in a field with high unmet medical needs.
Ultragenyx Pharmaceutical (NASDAQ: RARE) announced that they will present significant data from their investigational gene therapy programs at the ASGCT 25th Annual Meeting, scheduled for May 16-19, 2022. Key presentations include safety and efficacy results from DTX301 and DTX401 clinical trials. Notable sessions include oral presentations on Ornithine Transcarbamylase Deficiency and Glycogen Storage Disease Type Ia. Additionally, the company will showcase advancements in their manufacturing platform, Pinnacle PCL™. CEO Emil D. Kakkis will speak on accelerated approval for gene therapies.
Ultragenyx Pharmaceutical Inc. reported first-quarter 2022 revenue of $79.9 million, with Crysvita revenue at $54.6 million in its territories. The company reaffirmed its 2022 guidance for Crysvita revenue between $250 million and $260 million and Dojolvi revenue of $55 million to $65 million. The company's cash balance stood at approximately $814 million as of March 31, 2022. Despite revenue growth, net loss for the quarter reached $152.3 million, or $2.19 per share, reflecting increased operating expenses.
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) announced the grant of non-qualified stock options for 20,480 shares and 11,620 restricted stock units to two new non-executive officers. Approved by the compensation committee, these awards aim to attract talent under the Ultragenyx Employment Inducement Plan. The options have a ten-year term with an exercise price of $70.69 per share, equivalent to the closing price on April 29, 2022. The restricted stock units vest over four years, while the options vest gradually over the same period, contingent on ongoing employment.